Dr. Jonathan Rosenberg breaks down the data available for the bladder cohort from the DESTINY-PanTumor02 trial on trastuzumab deruxtecan in patients with HER2-expressing solid tumors.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.